FGFR3 and achondroplasia: Treatment options for achondroplasia are limited; currently, the only US Food and Drug Administration (FDA)-approved pharmacological intervention is vosoritide, a C-type natriuretic peptide analogue that binds to natriuretic peptide receptor B, thus reducing the activity of FGFR3 and allowing for bone growth.